Bortezomib mitigates adverse prognosis conferred by Bcl-2 overexpression in patients with relapsed/refractory multiple myeloma-Reference-Cited by-同舟云学术

Bortezomib mitigates adverse prognosis conferred by Bcl-2 overexpression in patients with relapsed/refractory multiple myeloma

Published:2011-12-06 Issue:6 Volume:53 Page:1174-1182
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Ailawadhi Sikander¹,Miecznikowski Jeff²,Gaile Dan P.²,Wang Dongliang³,Sher Taimur⁴,Mulligan George⁵,Bryant Barb⁵,Wilding Gregory E.²,Mashtare Terry²,Stein Leighton²,Masood Aisha⁴,Neuwirth Rachel⁵,Lee Kelvin P.⁴,Chanan-Khan Asher⁴

Affiliation:

1. Division of Hematology, University of Southern California, Los Angeles, CA, USA

2. Department of Biostatistics

3. Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY, USA

4. Department of Public Health and Preventive Medicine, SUNY Upstate Medical University, Syracuse, NY, USA

5. Millennium Pharmaceuticals, Cambridge, MA, USA

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

https://www.tandfonline.com/doi/pdf/10.3109/10428194.2011.637212